Oculis Holding AG

OCS
$14.12 (+ $0.59 + 4.36%)
Last updated: 2026-07-04 00:36 UTC
OCS Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINCH1242303498
Market Price14.12
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-2.76
Market Cap$1.2B
Book Value3.17
Price to Book6.536
Beta0.14
52w High23.08
52w Low14.0
Next Earnings DateN/A

Oculis Holding AG trades under ticker OCS on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN CH1242303498. Also searched as Oculis Holding.

Related researchOCS stock priceOCS share priceOculis Holding stockOculis Holding share price
About the Company
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Price History